Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 228,397,760 papers from all fields of science
Search
Sign In
Create Free Account
Selective Estrogen Receptor Degrader/Modulator RAD1901
Known as:
RAD1901
, SERD/SERM RAD1901
An orally available, selective estrogen receptor degrader (SERD) and selective estrogen receptor modulator (SERM), with potential antineoplastic and…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
X-ray crystal structure analysis of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), bound to estrogen receptor alpha ligand binding domain.
S. Fanning
,
G. Greene
,
M. Conlan
2020
Corpus ID: 219776981
e15647Background: Antiestrogens are a mainstay of treatment for estrogen receptor positive (ER+) breast cancer in both the…
Expand
2019
2019
Abstract P4-13-03: Elacestrant (RAD1901) demonstrates anti-tumor activity in models resistant to CDK4/6 inhibitors
H. Patel
,
N. Tao
,
H. Arlt
,
Teeru Bihani
Poster Session Abstracts
2019
Corpus ID: 165131300
2018
2018
Abstract P4-04-17: Elacestrant (RAD1901) demonstrates anti-tumor activity in a fulvestrant-resistant PDX model
H. Arlt
,
F. Garner
,
Teeru Bihani
2018
Corpus ID: 79659919
Background: Breast cancer is subdivided into categories based on tumor receptor status, with estrogen-receptor positive (ER…
Expand
2018
2018
Abstract P4-04-09: New oral SERD elacestrant (RAD1901) shows efficacy in breast cancer models harbouring ESR1 mutations and enhances the antiproliferative activity of mTORC1 and CDK4/6 inhibitors
L.-A. Martin
,
S. Pancholi
,
+5 authors
M. Dowsett
2018
Corpus ID: 79927277
Background: Targeting estrogen receptor (ER) signalling is the main therapeutic option for ER+ breast cancer (BC). However, over…
Expand
2017
2017
Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging…
G. Hattersley
,
A. Harris
,
J. Simon
,
G. Constantine
Menopause
2017
Corpus ID: 46881666
Objective: The aim of the study was to assess the efficacy and safety of RAD1901, an oral estrogen receptor ligand, for the…
Expand
2016
2016
A Phase 1 study of RAD1901, an oral selective estrogen receptor degrader, in ER positive, HER2 negative, advanced breast cancer patients.
E. D. Vries
,
Clasina M. Venema
,
+4 authors
F. Garner
2016
Corpus ID: 80387586
TPS627Background: RAD1901 is a novel, orally available selective estrogen receptor degrader (SERD) that binds to both mutant and…
Expand
2016
2016
A phase 1 dose escalation study of RAD1901, an oral selective estrogen receptor degrader, in healthy postmenopausal women
G. Hattersley
,
F. S. David
,
+7 authors
Gregory C. Williams
2016
Corpus ID: 78100756
Estrogen and the estrogen receptor (ER) are known to be prominent drivers of breast tumourigenesis and breast cancer progression…
Expand
2016
2016
Abstract OT2-01-10: A phase 1 study of RAD1901, a novel, orally available, selective estrogen receptor degrader, for the treatment of ER positive advanced breast cancer
W. Harb
,
F. Garner
,
+4 authors
D. Purandare
2016
Corpus ID: 76827101
The current NCCN treatment guidelines for ER+ breast cancer involves the use of approved agents such as fulvestrant, tamoxifen…
Expand
2016
2016
Abstract P3-05-07: RAD1901, a novel oral, selective estrogen receptor degrader (SERD) with single agent efficacy in an ER+ primary patent derived ESR1 mutant xenograft model
F. Garner
,
Jeffrey L. Brown
,
J. Katzenellenbogen
,
C. Lyttle
,
G. Hattersley
2016
Corpus ID: 76893128
Despite advances in the treatment of metastatic breast cancer, many women eventually relapse with more aggressive forms of…
Expand
2015
2015
A phase I study of RAD1901, an oral selective estrogen receptor degrader, in ER–positive, HER2–negative, postmenopausal advanced breast cancer patients.
W. Harb
,
F. Garner
,
+4 authors
G. Hattersley
2015
Corpus ID: 76745999
TPS638 Background: RAD1901 is a novel, non-steroidal, orally bioavailable selective estrogen receptor degrader (SERD…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE